Arovella Therapeutics Limited
Research Arovella Therapeutics Limited (ALA.AX) on Bullrun: market cap AUD 61.65M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALA.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 61.65M
- Financial periodFY2026
- Net income-AUD 6.92M
- Free cash flow-AUD 6.95M
Valuation Snapshot
latest market cap is AUD 61.65M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | -AUD 6.92M | -AUD 6.95M | n/a | -0.01 | AUD 14.35M | n/a | AUD 14.15M |
| FY2025 | AUD 136.00K | -AUD 7.51M | -AUD 7.34M | 100.0% | -0.01 | AUD 20.88M | n/a | AUD 20.08M |
| FY2024 | AUD 17.00K | -AUD 8.75M | -AUD 7.04M | 100.0% | -0.01 | AUD 12.71M | n/a | AUD 11.23M |
| FY2023 | AUD 405.90K | -AUD 10.18M | -AUD 6.40M | 49.9% | -0.01 | AUD 5.18M | n/a | AUD 3.78M |
| FY2022 | AUD 295.81K | n/a | n/a | 30.0% | n/a | n/a | AUD 144.80K | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | AUD 61.65M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Arovella Therapeutics Limited
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Arovella Therapeutics Limited's market cap?
Arovella Therapeutics Limited's market capitalization is AUD 61.65M.
What does Arovella Therapeutics Limited do?
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors.